Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lance Smith

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
BMC Bioinformatics|September 24, 2015
Group-based variant calling leveraging next-generation supercomputing for large-scale whole-genome sequencing studiesKristopher A Standish, Tristan M Carland, Glenn K Lockwood, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
BMC Bioinformatics|September 24, 2015
Group-based variant calling leveraging next-generation supercomputing for large-scale whole-genome sequencing studiesKristopher A Standish, Tristan M Carland, Glenn K Lockwood, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Pageof 2